- Several FDA-approved alternatives to Wegovy exist, each with different mechanisms, costs, and weight loss outcomes
- Zepbound (tirzepatide) produced greater average weight loss than Wegovy in head-to-head trials
- Phentermine is often the most affordable option and is covered by nearly all insurance
- PEAK does not prescribe compounded semaglutide—we focus on FDA-approved medications with verified safety
- If your insurer denied Wegovy, PEAK can help with appeals and alternative coverage pathways
Why patients look for Wegovy alternatives
Not everyone who wants Wegovy can access it. Wegovy is an effective medication, but the reality of getting it—and affording it—is a different conversation entirely. Patients come to PEAK looking for alternatives for several common reasons:
- Insurance doesn't cover it (or coverage was denied after prior authorization review)
- The cost without insurance is often prohibitive—Wegovy's cash price is typically high
- Side effects are intolerable—persistent nausea, vomiting, or GI issues that don't resolve with dose adjustments
- Step therapy requirements delay access by months while you try other medications first
If you're in any of these situations, you have options. The FDA has approved multiple medications for chronic weight management, and each works through a different mechanism. The goal is to find the one that fits your medical history, insurance coverage, and treatment goals.
Zepbound (tirzepatide)
The closest clinical alternative
Zepbound is a dual GIP/GLP-1 receptor agonist—meaning it targets two appetite-regulating hormones instead of the single GLP-1 pathway that Wegovy uses. In head-to-head clinical trials, tirzepatide produced greater average weight loss than semaglutide: up to 22.5% of body weight compared to approximately 15% with Wegovy.
Like Wegovy, Zepbound is a weekly injection. Insurance coverage varies but is expanding rapidly. Importantly, Zepbound also offers a cash-pay vial option that is significantly more affordable than Wegovy's cash-pay pricing.
If your reason for seeking an alternative is insurance coverage, Zepbound may be covered even when Wegovy isn't—different formulary decisions by different payers. PEAK verifies your specific coverage before prescribing.
Phentermine
A fundamentally different medication
Phentermine is not a GLP-1. It's a daily oral tablet that suppresses appetite through sympathomimetic stimulation—a completely different mechanism than Wegovy. It produces 5–10% body weight loss, which is less dramatic than GLP-1 outcomes, but it comes with advantages that matter to many patients.
- Extremely affordable: generic versions are usually low cost
- Insurance coverage: Covered by nearly all insurance plans
- Administration: Daily oral tablet (no injections)
- FDA approval: Approved for short-term use (typically 12 weeks, though clinicians may prescribe longer based on response)
Phentermine is particularly good for patients who need immediate, affordable treatment while waiting for GLP-1 insurance coverage to resolve. It's also commonly used to fulfill step therapy requirements and as a bridge to GLP-1 therapy or in combination with a GLP-1 later.
Contrave (naltrexone/bupropion)
Oral dual-mechanism medication
Contrave combines two medications into one: naltrexone, which reduces food cravings and the reward response to eating, and bupropion, which suppresses appetite and has mood-improving properties. Together, they produce an average of approximately 5–6% body weight loss.
Contrave is particularly effective for patients whose overeating is driven by emotional eating, food cravings, or reward-seeking behavior. Unlike phentermine, Contrave is approved for long-term use, making it suitable for sustained weight management.
- Cost: varies by insurance and pharmacy
- Administration: Daily oral tablet
- Best for: Emotional eaters, patients with cravings-driven eating patterns
- FDA approval: Chronic weight management (long-term use)
Contrave carries a black box warning for suicidal thoughts and behavior.
Saxenda (liraglutide)
First-generation GLP-1 for weight loss
Saxenda was the first GLP-1 receptor agonist approved specifically for weight management. It uses liraglutide—the same active ingredient as the diabetes medication Victoza—at a higher dose. Unlike Wegovy's weekly injection, Saxenda requires daily injection.
Saxenda produces approximately 8% body weight loss, which is less than Wegovy but still clinically meaningful. It works through the same GLP-1 mechanism, so the experience is similar: reduced appetite, slower gastric emptying, and improved satiety signals.
- Advantages: Longer clinical track record, may be covered by insurance plans that don't cover Wegovy
- Cost: Insurance coverage varies; cash price is often high without coverage
- Administration: Daily injection (not weekly)
- Good for: Patients who want a GLP-1 approach but can't access Wegovy or Zepbound
Combination approaches
Some patients do best with multiple medications working together. Combination therapy is a well-established approach in obesity medicine, and your PEAK clinician may recommend it based on your individual response and goals.
Phentermine + GLP-1 is a common combination. The appetite-suppressing effects of phentermine complement the metabolic and satiety benefits of GLP-1 medications, and some patients achieve greater weight loss with both than with either medication alone.
Your clinician may also recommend starting with an affordable alternative—like phentermine or Contrave—and adding or transitioning to a GLP-1 medication as your insurance coverage evolves or as step therapy requirements are satisfied.
What about compounded semaglutide?
PEAK does not prescribe compounded semaglutide. While cheaper and more accessible through some telehealth platforms, compounded versions have not undergone FDA review for safety, efficacy, and manufacturing consistency.
With FDA enforcement tightening on compounded GLP-1 medications, the long-term availability of these products is uncertain. Patients who start on compounded semaglutide may find themselves without access when enforcement actions take effect.
PEAK focuses exclusively on FDA-approved alternatives that provide verified safety, consistent dosing accuracy, and established clinical evidence. We believe this is the responsible approach for patients who deserve reliable, evidence-based treatment.
Important safety information: All GLP-1 receptor agonists (Wegovy, Zepbound, Saxenda) carry a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. They are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
Quick comparison
| Medication | Type | Avg Weight Loss | Cost | How Taken |
|---|---|---|---|---|
| Zepbound | Dual GIP/GLP-1 | up to 22.5% | Insurance or self-pay (vial) | Weekly injection |
| Phentermine | Appetite suppressant | ~5–10% | Often low cost | Daily tablet |
| Contrave | Naltrexone/bupropion | ~5–6% | Varies by plan/pharmacy | Daily tablet |
| Saxenda | GLP-1 agonist | ~5–8% | Insurance or self-pay | Daily injection |
The best alternative to Wegovy is the one that fits your medical profile, your insurance coverage, and your treatment goals—not necessarily the one with the most impressive clinical trial numbers.
We file appeals, explore alternative coverage pathways, and prescribe equally effective alternatives while the appeal process plays out. Many Wegovy denials are overturned on appeal—especially with proper clinical documentation and persistence.
